Previous Close | 15.91 |
Open | 19.00 |
Bid | 16.70 |
Ask | 19.60 |
Strike | 110.00 |
Expire Date | 2024-06-21 |
Day's Range | 19.00 - 19.00 |
Contract Range | N/A |
Volume | |
Open Interest | 128 |
Comparative Analysis of Q1 2024 Financial Performance Against Analyst Expectations
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2024, which include the consolidated financial results for GRAIL.
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.